The Indian Council for Medical Research (ICMR), New Delhi, is looking
out for private partners to commercialize various compounds and
technologies. With an aim to promote Public Private Partnerships,
the premier medical regulatory authority invited applications from
various companies to commercialize products.
The different compounds that are being looked upon for
commercialization include a herbal insecticidal composition, an
antineoplastic compound, a herbal composition useful as larvicide agent
against dengue vector, use of formulation comprising human SP-D for
therapy and prevention of sexually transmitted infection including HIV.
The technologies that are being put for industrial collaborations are
the Dot ELISA for diagnosis of sequelae to Chlamydia trachomatis
infection in women using Chlamydial Heat Shock Protein-60, An
Immunodiagnostic Reagent Macrofilricidal Agents for Filariasis Control,
A cyclic lipopeptide of Bacillus subtilis ssp. subtilis (VCRC- B471)
with potential to kill mosquito stages, A process for pot staining of
sputum for detection of Acid fast Bacilli.
The Indian patents have been already filed for few of the technologies
by the Intellectual Property Right (IPR) cell of the ICMR. With such
kind of innovative products and technologies made available, the
private industry is expected to react positively to promote them.
IMB scientists find cause of rare skin
Institute of Medical Biology (IMB) scientists under the Agency of
Science, Technology and Research (A*STAR) in Singapore are part of an
international team of researchers who became the first in the world to
discover the gene behind a rare skin cancer which grows rapidly for a
few weeks before healing spontaneously, according to the research
The peculiar behaviour of this rare self-healing cancer, called
multiple self-healing squamous epithelioma (MSSE), was discovered to be
caused by a failure in the gene called TGFBR1, which is a key component
of a signalling pathway that can also be impaired in other cancers.
This pathway is widely regarded in the field as a potential target for
therapeutic intervention in cancer treatment.
Dr David Goudie, a clinical genetics consultant at Dundee University
and a long term specialist in MSSE, said, “The unusual behaviour of
this tumor has baffled scientists for over 40 years, so we are excited
to have discovered the genetic faults that cause the disease.
Understanding how tumors that lack TGFBR1 behave will surely help us to
predict the clinical effects of drugs that target these
cancer-promoting or cancer-inhibiting signals.”